Status:

COMPLETED

Neurovascular Changes Induced by Chemotherapy

Lead Sponsor:

University of Sao Paulo General Hospital

Conditions:

Breast Cancer

Chemotherapeutic Toxicity

Eligibility:

FEMALE

35-65 years

Phase:

NA

Brief Summary

The purpose of the present study was to test the hypothesis that doxorubicin and cyclophosphamide adjuvant chemotherapy (CHT) acutely induces neurovascular and hemodynamic changes in patients with bre...

Detailed Description

The purpose of the present study was to test the hypothesis that doxorubicin and cyclophosphamide adjuvant chemotherapy (CHT) acutely induces neurovascular and hemodynamic changes in patients with bre...

Eligibility Criteria

Inclusion

  • Breast cancer patients and prescription of adjuvant chemotherapy with antracycline and cyclophosphamide

Exclusion

  • Metastic disease
  • Hypercholesterolemia
  • Diabetes
  • Hypertension
  • Severe lymphedema
  • Renal insufficient
  • Heart failure
  • Chronic liver disease
  • Obesity, and treatment with some medications that inhibit cardiotoxicity, as beta-blocker angiotensin converting enzyme, statin, losartan and antioxidants.

Key Trial Info

Start Date :

February 22 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2017

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT03339804

Start Date

February 22 2016

End Date

October 1 2017

Last Update

November 13 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Heart Institute

São Paulo, Cerqueira Cesar, Brazil